Down 2.8% to $10.69, Vivus (NASDAQ:VVUS), is one of today's notable movers. The Dow Jones Industrial Average is now trading fractionally lower to 14,557 and the S&P is trading 0.5% lower to 1,561.
Vivus share prices have moved between a 52-week high of $31.21 and a 52-week low of $9.86 and are now trading 8% above that low price at $10.69 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.1% while the 200-day MA has slid 1.5%.
VIVUS, Inc. develops and manufactures therapies for the treatment of men with erectile dysfunction. The Company is currently marketing MUSE and ACTIS in the United States and has license agreements with other companies to market its products internationally. VIVUS is also conducting clinical trials for another treatment.
Potential upside of 63.7% exists for Vivus, based on a current level of $10.69 and analysts' average consensus price target of $17.50. The stock should run into initial resistance at its 50-day moving average (MA) of $12.11 and subsequent resistance at its 200-day MA of $17.51.